Experimental drug aims to tame stubborn autoimmune diseases
NCT ID NCT07655453
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. Up to 36 adults aged 18 to 75 with certain blood cell markers can join.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- STR-P005
- What this could lead to
- If successful, this could point toward a new treatment option for people with autoimmune diseases that have not responded to standard therapies.
- What could go wrong
- This is a very early, small study (36 people) focused mainly on safety. The drug may not work as hoped, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug STR-P005 aims to tame stubborn autoimmune diseases
- Experimental CAR t therapy takes on autoimmune diseases
- Experimental cell therapy takes on stubborn autoimmune diseases
- Engineered immune cells take on autoimmune diseases in early trial
- Immune reset: CAR-T therapy takes on autoimmune diseases